Fixing a $5 Trillion Problem by Rewriting the Rules of Healthcare | By Mark Newman, CEO of Nomi Health

The real question isn’t whether healthcare can be fixed—it’s whether we’re ready to accelerate the change or stay stuck in a broken, outdated model.
FDA Approves LANCELOT Technology for Corcym’s Perceval Plus, Enhancing Performance of Sutureless Aortic Valve Replacement
Lancelot Technology: CORCYM , the medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the integration of LANCELOT technologies into Perceval Plus after recent approval from the U.S. regulatory agency FDA, Food & Drug Administration. “For many years, Perceval has been well-known as […]
AION Labs, In Continued Partnership with BioMed X, Launches 2025 Global Call for Applications: Generative AI for Novel Target Combinations
Title
AION Labs Announces 2025 Global Call for AI Applications
Description
AION Labs partners with BioMed X to launch an AI-driven platform for innovative medical device applications in 2025.
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
TNKase is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care, Activase, which is administered as an IV bolus followed by a 60-minute infusion. Genentech will also be introducing a new 25 mg vial configuration in the coming months to support the approval of TNKase for AIS.
Latent TB Testing Market Research 2025
The “Latent TB Testing Market (2025 Edition): Analysis By Test Type (Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA)), By End User, By Region, By Country: Market Insights and Forecast (2020-2030)” report has been added to ResearchAndMarkets.com’s offering.
Wren Laboratories Announces Discontinuation of NETest 1.0 in Favor of Advanced NETest 2.0
“Clinicians need a reliable, data-driven tool to make informed treatment decisions,” added Dr. Mark Kidd, Laboratory Director at Wren Laboratories. “With NETest 2.0, we’ve significantly enhanced diagnostic precision, allowing for improved patient surveillance and better treatment outcomes.”
Boston Scientific Reveals Agreement to Acquire SoniVie Ltd.
“Renal denervation for hypertension is an exciting medical advancement for the millions of patients it may help and is supported by positive results from contemporary clinical trials and ongoing research,” said Lance Bates, senior vice president and president, Interventional Cardiology Therapies, Boston Scientific. “We believe the addition of the differentiated, ultrasound-based TIVUS system can complement our expansive interventional portfolio with a minimally invasive therapy for patients with hypertension and provides opportunity for future advancements in this space.”
Why You Should Give Plasma: Benefits and Impact on Your Community

Plasma makes up about 55% of human blood and is often referred to as liquid gold due to its golden-yellow appearance. It plays a crucial role in the human body, acting as a transport medium for cells, nutrients, hormones, and waste products. Plasma is primarily composed of water (about 90%), but it also contains various […]
Why Is It That Sword Mounting Was Important for Samurai?

This article investigates its profound importance for Samurais as it affected their martial, cultural and personal lives.
Trinity Biotech Secures Additional Funding for Glucose Monitoring Tech
Trinity Biotech notes the additional liquidity will support both the continued development of their innovative continuous glucose monitoring (CGM) technology and the Company’s comprehensive transformation plan.
WORK Medical Technology Group Partners with Chartwell Medical
Mr. Wu Shuang, CEO and chairman of the board of directors of WORK Medical Technology Group, commented, “We are delighted to enter into a strategic partnership with Chartwell Medical. This collaboration reflects our shared commitment to mutual growth and innovation. By leveraging our combined strengths and resources, we aim to enhance operational efficiency, market leadership, and international competitiveness. In addition, our mutual goal is to advance high-end medical technologies, strengthen competitiveness in the global healthcare industry, and accelerate the adoption of cutting-edge solutions in domestic markets.”
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
“The CHMP’s recommendation for approval of VYJUVEK is an exciting step towards our goal of delivering the first ever corrective therapy to DEB patients across Europe,” said Suma Krishnan, President of Research and Development at Krystal Biotech. “The CHMP’s support for a broad label, including treatment of patients from birth and the option of patient or caregiver administration at home, are also fantastic outcomes for the DEB patients we aim to serve, broadening access and reducing barriers to starting on and staying on therapy.”